Evidence map›Paper›PMID 38725005›Full record

ArticleWorld journal of surgical oncology2024

METTL14 regulates CD8

Chongqi Sun, Jian Wang, Huixing Li, Luyao Liu, Yu Lin, Ling Zhang, Xianglong Zu, Yizhi Zhu, Yongqian Shu, Dong Shen and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of surgical oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. mFrontiers in immunology · 2026
    Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chongqi Sun *Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
Jian Wang *Department of Oncology, Wuxi Second Geriatric Hospital, Wuxi, Jiangsu, 214174, China.
Huixing Li *Department of Thoracic Surgery, The Affiliated Wuxi People's Hospital of Nanjing Medical University, Wuxi, Jiangsu, 214023, China.
Luyao LiuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
Yu LinDepartment of Oncology, The Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou, Jiangsu, 215001, China.
Ling ZhangDepartment of Oncology, Jintan Hospital Affiliated to Jiangsu University, Changzhou, Jiangsu, 213200, China.
Xianglong ZuNanjing Medical University, Nanjing, Jiangsu, 210029, China.
Yizhi ZhuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
Yongqian ShuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China.
Dong ShenDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu, 214400, China.
Qiong WangDepartment of Oncology, The Affiliated Jiangyin Hospital of Nantong University, Jiangyin, Jiangsu, 214400, China. wangqiong55@hotmail.com.
Yiqian LiuDepartment of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, 210029, China. liuyiqian@njmu.edu.cn.

Funding

National Natural Science Foundation of China No. 82003094
6 · The paper itself

Abstract

backgroundN6-methyladenosine (m6A) modification plays an important role in lung cancer. However, methyltransferase-like 14 (METTL14), which serves as the main component of the m6A complex, has been less reported to be involved in the immune microenvironment of lung cancer. This study aimed to analyze the relationship between METTL14 and the immune checkpoint inhibitor programmed death receptor 1 (PD-1) in lung cancer.

methodsCCK-8, colony formation, transwell, wound healing, and flow cytometry assays were performed to explore the role of METTL14 in lung cancer progression in vitro. Furthermore, syngeneic model mice were treated with sh-METTL14 andan anti-PD-1 antibody to observe the effect of METTL14 on immunotherapy. Flow cytometry and immunohistochemical (IHC) staining were used to detect CD8 expression. RIP and MeRIP were performed to assess the relationship between METTL14 and HSD17B6. LLC cells and activated mouse PBMCs were cocultured in vitro to mimic immune cell infiltration in the tumor microenvironment. ELISA was used to detect IFN-γ and TNF-α levels.

resultsThe online database GEPIA showed that high METTL14 expression indicated a poor prognosis in patients with lung cancer. In vitro assays suggested that METTL14 knockdown suppressed lung cancer progression. In vivo assays revealed that METTL14 knockdown inhibited tumor growth and enhanced the response to PD-1 immunotherapy. Furthermore, METTL14 knockdown enhanced CD8

conclusionThe disruption of METTL14 contributed to CD8

Indexed as

CD8-Positive T-LymphocytesImmune Checkpoint InhibitorsLung NeoplasmsMethyltransferasesProgrammed Cell Death 1 ReceptorTumor MicroenvironmentAnimalsCell ProliferationFemaleImmunotherapyLymphocyte ActivationMiceMice, Inbred C57BLPrognosisTumor Cells, CulturedImmune Checkpoint InhibitorsMethyltransferasesMettl14 protein, mousePDCD1 protein, humanProgrammed Cell Death 1 ReceptorCD8+ T cellHSD17B6Lung cancerMETTL14PD-1

Identifiers

PMID38725005
PMCPMC11083848

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.